Top Qs
Timeline
Chat
Perspective
ETH-LAD
Chemical compound From Wikipedia, the free encyclopedia
Remove ads
ETH-LAD, or ETHLAD, also known as 6-ethyl-6-nor-lysergic acid diethylamide (6-ethyl-6-nor-LSD), is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD; also known as METH-LAD).[4][5] It is slightly more potent than LSD and is among the most potent psychedelics known.[6][4][7][2][8][9] The drug has been encountered as a novel designer drug in Europe.[10][11] In addition, a prodrug of ETH-LAD, 1P-ETH-LAD, has been developed and encountered.[12][13]
Remove ads
Use and effects
ETH-LAD is slightly more potent than LSD in both animals and humans.[4][7][6][5][14][9] It is about 1.6- to 2.3-fold more potent than LSD in rodent drug discrimination tests.[7][6][5][9] The drug's human dose range is 20 to 150 μg orally, compared to a range of 50 to 200 μg given for LSD, and it is said to be roughly twice as potent as LSD in humans.[1][2][4][8][9] As such, ETH-LAD is one of the most potent serotonergic psychedelics in humans known, if not the most potent known psychedelic.[6][4][7][8][9] Moreover, it has been said that LSD can no longer be considered the most potent psychedelic.[15] ETH-LAD's duration is 8 to 12 hours as with LSD.[1]
The qualitative effects of ETH-LAD are similar to those of LSD.[7][1] In a limited number of anecdotal reports collected and published by Alexander Shulgin in TiHKAL however, ETH-LAD was described as more gentle and as less pushy, demanding, and aggressive than LSD, but also as having less of LSD's sparkle.[1] ETH-LAD was said to have a greatly modified degree of visual distortion relative to LSD as well.[1]
Remove ads
Interactions
Pharmacology
ETH-LAD acts as a serotonin receptor agonist, including of the serotonin 5-HT2A receptor.[16][17] It shows greater potency and efficacy as a serotonin 5-HT2A receptor agonist than LSD in vitro.[16] In addition to the serotonin 5-HT2A receptor, the drug binds with high affinity to the serotonin 5-HT1A and 5-HT2C receptors.[16] Like LSD, ETH-LAD also binds with lower affinity to the dopamine D1, D2, D3, D4, and D5 receptors.[16][18]
ETH-LAD shows psychedelic-like effects in animals, specifically rodent drug discrimination tests.[7][6][14] Similarly to LSD, ETH-LAD shows moderate anti-inflammatory effects in preclinical research, but with slightly higher potency.[17]
Chemistry
According to Alexander Shulgin, ETH-LAD may be chemically unstable in solution.[1]
Analogues of ETH-LAD include LSD, PRO-LAD, FLUORETH-LAD, and AL-LAD among others. In addition, ALD-52, LSZ, and LSM-775 are analogues of ETH-LAD. 1P-ETH-LAD, a prodrug of ETH-LAD, has been developed and encountered.[12][13]
History
ETH-LAD was first described in the scientific literature by at least 1976.[19] Subsequently, its preclinical pharmacology was studied and described by Andrew J. Hoffman and David E. Nichols in 1985.[14] ETH-LAD's properties and effects in humans were assessed by Alexander Shulgin.[8][9] These were reported via personal communication by Nichols in 1986[9][15] and later described by Alexander Shulgin himself in a 1994 literature review[8] and in his 1997 book TiHKAL (Tryptamines I Have Known and Loved).[1] ETH-LAD was encountered as a novel designer drug in Europe by 2016.[10][11]
Remove ads
Society and culture
Legal status
United Kingdom
On June 10, 2014, the United Kingdom Advisory Council on the Misuse of Drugs (ACMD) recommended that ETH-LAD be specifically named in the UK Misuse of Drugs Act as a class A drug despite not identifying it as ever having been sold or any harm associated with its use.[20] The UK Home office accepted this advice and announced a ban of the substance to be enacted on 6 January 2015.[21]
Switzerland
ETH-LAD is illegal in Switzerland as of December 2015.[22]
Remove ads
References
External links
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads